Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CEL001
- Development stage
- Phase 1
- Lead developer
- Xiling Biotechnology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CEL001 is an adoptive natural killer (NK) cell therapy being developed by Guangzhou Xiling Biotechnology for the treatment of advanced solid tumors. As a cell-based immunotherapy, it utilizes the innate cytotoxic potential of NK cells to identify and eliminate malignant cells that have escaped standard therapies. The treatment is currently being evaluated in a Phase 1 dose-escalation and expansion clinical trial to determine its safety, tolerability, and preliminary efficacy in patients with refractory or intolerant solid tumors. The therapy is administered as an injection, and the developer operates a GMP-compliant facility in China for its production.
- Other names
- CEL001 injectionCEL-001 injectionCEL 001 injectionNK cell preparation
02
Targets
MHC I (MHC class I})
Beyond the preview
Go deeper on CEL001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEL001.